CagriSema's Weakness in Blood Sugar Control Revealed

Novo Nordisk's (NVO) CagriSema is a once-weekly subcutaneous injection that combines cagrilintide, a long-acting amylin receptor agonist, and semaglutide, a GLP-1 receptor agonist. In the 68-week Phase 3 REIMAGINE-4 trial involving approximately 1,000 patients with type 2 diabetes, the mean weight reduction in the compliant group was 15.2%, meeting the non-inferiority criteria compared to Eli Lilly's (LLY) Mounjaro (tirzepatide, a dual GIP/GLP-1 receptor agonist) at 15.8%. However, the reduction in glycated hemoglobin (HbA1c) was 1.9 percentage points, failing to meet the non-inferiority criteria compared to tirzepatide's 2.2 percentage points. This indicates that while it demonstrated efficacy in obesity, it failed to differentiate itself in blood sugar control, a key factor in diabetes treatment.

Regulatory Value Remains, but Competitive Positioning Weakens

CagriSema also showed a weight reduction rate of 23.0% in the 84-week compliant group in the Phase 3 REDEFINE-4 trial for obese patients, falling short of Zepbound (tirzepatide) at 25.5% and failing to achieve the non-inferiority goal. However, Novo Nordisk has submitted an application for obesity indication to the U.S. Food and Drug Administration (FDA) based on the REDEFINE-1 and REDEFINE-2 data, with a company-scheduled decision date in the fourth quarter of 2026. If approved, it will be the first once-weekly GLP-1/amylin combination therapy, but its competitive positioning has weakened due to its failure to outperform tirzepatide in two head-to-head Phase 3 trials, making the argument for premium pricing and market share expansion less compelling. The current standard competitors are Mounjaro, Zepbound, and Wegovy (semaglutide), and emerging threats include Lilly's Phase 3 oral GLP-1 orforglipron and Phase 3 GLP-1/GIP/glucagon triple agonist retatrutide.

Cardiovascular Diversification and CB1 Strategy Also Shaken

Ziltivekimab, an interleukin-6 ligand-blocking antibody, failed to reduce the composite endpoint of cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke (3-point MACE) in the Phase 3 ZEUS trial, which evaluated 6,200 patients with atherosclerotic cardiovascular disease, chronic kidney disease, and inflammation. The company is continuing the Phase 3 HERMES trial in heart failure patients and the Phase 3 ARTEMIS trial in acute myocardial infarction patients, with results expected in the first half of 2027. Meanwhile, monlunabant (INV-202), a peripherally selective CB1 inverse agonist, was discontinued in Phase 2 development due to observed neuropsychiatric adverse events, resulting in an impairment of 4 billion Danish kroner of related intangible assets. The case of Sanofi's Acomplia (rimonabant), which was approved in Europe in 2006 but withdrawn in 2009 due to psychiatric risks, highlights the safety hurdles associated with the CB1 class.

Declining Internal Productivity Increases Demand for Bolt-on Acquisitions

CEO Mike Doustdar has stated that the company will prioritize bolt-on transactions that can be readily integrated into its diabetes and obesity base rather than large, transformative acquisitions. Given that Novo Nordisk acquired Inversago Pharma for up to $1.075 billion in cash, including development and commercial milestones, and subsequently discontinued its key assets, future transactions will likely place greater emphasis on safety validation and risk-sharing in later-stage clinical development. With Morgan Stanley projecting the type 2 diabetes and obesity GLP-1 market to reach $190 billion by 2035, the recent setbacks in late-stage clinical trials increase the pressure to secure new mechanisms to close the gap with Lilly. This creates more opportunities for partnerships with early- and mid-stage metabolic disease biotech companies, but acquisition prices are likely to be more rigorously determined based on clinical validation and differentiated efficacy.